Lilly Asia Ventures

• Lilly Asia Ventures is the corporate venture capital arm of Eli Lilly and Company focused on the Asia-Pacific region. The fund invests in healthcare and life sciences companies, particularly those developing innovative therapeutics, medical devices, and digital health solutions. LAV seeks to identify and support promising startups that align with Lilly's strategic interests in advancing healthcare innovation across Asia.

Companies from this investor’s TAAFT profile, ranked by latest known raise. Round details come from our company catalog.

Companies

1

Latest raises tracked

$68.7M

With round data

1

Stages seen

Seed

• 

  Excalipoint Therapeutics

  Biotechnology · China

  $68.70M raised
  Seed Announced 6 investors

  Valuation

  $300M

  Announced 18 Mar 2026

  Company